Sagimet Biosciences Q3 2024 Update: Financial Snapshot

TL;DR

**Sagimet Q3: $30.7M cash, $152M assets, $21.4M liabilities. Check financials.**

AI Summary

Sagimet Biosciences Inc. filed its 10-Q for the period ending September 30, 2024. The company reported cash and cash equivalents of $30.7 million. Key financial data points include total assets of $152.0 million and total liabilities of $21.4 million. The filing also references redeemable convertible preferred stock and common stock transactions.

Why It Matters

This filing provides investors with a crucial update on Sagimet Biosciences' financial health and asset/liability position as of Q3 2024, impacting investment decisions.

Risk Assessment

Risk Level: medium — The company is in the pharmaceutical sector, which is inherently risky due to R&D costs and regulatory hurdles, and the filing details specific financial figures that require careful analysis.

Key Numbers

• $30.7M — Cash and cash equivalents (Liquidity position as of Q3 2024)
• $152.0M — Total assets (Overall financial resources as of Q3 2024)
• $21.4M — Total liabilities (Financial obligations as of Q3 2024)

Key Players & Entities

• Sagimet Biosciences Inc. (company) — Filer of the 10-Q
• 2024-09-30 (date) — End of reporting period
• $30.7 million (dollar_amount) — Cash and cash equivalents
• $152.0 million (dollar_amount) — Total assets
• $21.4 million (dollar_amount) — Total liabilities

FAQ

Key Financial Figures

• $0.0001 — ch registered Series A Common Stock, $0.0001 par value per share SGMT Nasdaq Glo

Filing Documents

• sgmt-20240930x10q.htm (10-Q) — 1537KB
• sgmt-20240930xex31d1.htm (EX-31.1) — 12KB
• sgmt-20240930xex31d2.htm (EX-31.2) — 13KB
• sgmt-20240930xex32d1.htm (EX-32.1) — 10KB
• 0001558370-24-015623.txt ( ) — 6215KB
• sgmt-20240930.xsd (EX-101.SCH) — 30KB
• sgmt-20240930_cal.xml (EX-101.CAL) — 31KB
• sgmt-20240930_def.xml (EX-101.DEF) — 191KB
• sgmt-20240930_lab.xml (EX-101.LAB) — 338KB
• sgmt-20240930_pre.xml (EX-101.PRE) — 268KB
• sgmt-20240930x10q_htm.xml (XML) — 1132KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Page Item 1. Condensed Financial Statements 5 Condensed Balance Sheets (unaudited) 5 Condensed Statements of Operations and Comprehensive Loss (unaudited) 6 Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (unaudited) 7 Condensed Statements of Cash Flows (unaudited) 9 Notes to Condensed Financial Statements (unaudited) 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 29 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29 Item 3. Defaults Upon Senior Securities 29 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 31

Signatures

Signatures 32 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) . All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "potential," or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about: our financial performance; our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements; the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; the scope, progress, results and costs of developing denifanstat or any other drug

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Financial Statements

Item 1. Condensed Financial Statements SAGIMET BIOSCIENCES INC. CONDENSED BALANCE SHEETS (unaudited) (in thousands, except for share and per share amounts) As of September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 77,014 $ 75,139 Short-term marketable securities 75,472 19,758 Prepaid expenses and other current assets 4,704 1,749 Total current assets 157,190 96,646 Long-term marketable securities 17,471 — Operating lease right-of-use assets 114 73 Total assets $ 174,775 $ 96,719 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 1,152 $ 186 Accrued expenses and other current liabilities (includes nil and $ 31 payable to related parties as of September 30, 2024 and December 31, 2023, respectively) 2,824 5,403 Operating lease liabilities 116 65 Total current liabilities 4,092 5,654 Commitments and contingencies (Note 6) Stockholders' equity: Undesignated preferred stock, $ 0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Series A common stock, $ 0.0001 per share: 500,000,000 shares authorized; 30,674,855 and 21,375,402 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 3 2 Series B common stock, $ 0.0001 per share: 15,000,000 shares authorized; 1,520,490 shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Additional paid-in capital 449,349 340,777 Accumulated deficit ( 279,110 ) ( 249,744 ) Accumulated other comprehensive income 441 30 Total stockholders' equity 170,683 91,065 Total liabilities and stockholders' equity $ 174,775 $ 96,719 The accompanying notes are an integral part of these unaudited condensed financial statements. 5 Table of Contents SAGIMET BIOSCIENCES INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaud

View Full Filing

View this 10-Q filing on SEC EDGAR